Single Test Detects All Existing Strains of H5N1
|
By LabMedica International staff writers Posted on 06 Jun 2012 |
A bird flu diagnostic kit was successfully developed by scientists at a research institute and a hospital in Singapore.
The advanced kit enables doctors to rapidly detect all existing strains of H5N1 viruses in a single test with almost 100% accuracy. This will boost the public healthcare system and will aid pandemic preparedness worldwide against this highly infectious and often lethal disease.
The new H5N1 test kit is more accurately known as the H5N1 real-time Reverse Transcription Polymerase Chain Reaction (RT-PCR) assay. It is the only detection kit currently available on the market that can accurately and rapidly detect all known strains of the H5N1 avian Influenza A virus.
The current gold standard for H5N1 detection recommended by the World Health Organization (WHO; Geneva, Switzerland) is only able to detect three out of the 10 distinct genetic groups (clades 1, 2, and 3). To detect all existing strains of H5N1 with the WHO detection method is not possible.
Codeveloped by Dr. Masafumi Inoue, a senior research scientist and project director of technology development from the Experimental Therapeutics Center (ETC) under the Agency for Science and Technology Research (A*STAR; Singapore) and Dr Timothy Barkham, a senior consultant of Laboratory Medicine from Tan Tock Seng Hospital (TTSH; Singapore), the newly launched H5N1 test kit has been clinically validated by several hospitals in Southeast Asia.
The new test kit is compatible with the previously launched "4-plex" Influenza diagnostic kit. The latter is being used by several regional hospitals in Thailand. Using such multiplex assays enables simultaneous detection and differentiation of the different types of influenza infection in a single test, which will save laboratories time and expense.
"We are excited to be able to contribute to the fight against H5N1 virus with our expertise and know-how. Our technology has greatly simplified and accelerated the process of detection and identification of new H5N1 variants. Such information is especially critical when the virus mutates to become more dangerous, such as in drug resistance." said Dr Inoue.
Related Links:
Agency for Science and Technology Research
Tan Tock Seng Hospital
World Health Organization
The advanced kit enables doctors to rapidly detect all existing strains of H5N1 viruses in a single test with almost 100% accuracy. This will boost the public healthcare system and will aid pandemic preparedness worldwide against this highly infectious and often lethal disease.
The new H5N1 test kit is more accurately known as the H5N1 real-time Reverse Transcription Polymerase Chain Reaction (RT-PCR) assay. It is the only detection kit currently available on the market that can accurately and rapidly detect all known strains of the H5N1 avian Influenza A virus.
The current gold standard for H5N1 detection recommended by the World Health Organization (WHO; Geneva, Switzerland) is only able to detect three out of the 10 distinct genetic groups (clades 1, 2, and 3). To detect all existing strains of H5N1 with the WHO detection method is not possible.
Codeveloped by Dr. Masafumi Inoue, a senior research scientist and project director of technology development from the Experimental Therapeutics Center (ETC) under the Agency for Science and Technology Research (A*STAR; Singapore) and Dr Timothy Barkham, a senior consultant of Laboratory Medicine from Tan Tock Seng Hospital (TTSH; Singapore), the newly launched H5N1 test kit has been clinically validated by several hospitals in Southeast Asia.
The new test kit is compatible with the previously launched "4-plex" Influenza diagnostic kit. The latter is being used by several regional hospitals in Thailand. Using such multiplex assays enables simultaneous detection and differentiation of the different types of influenza infection in a single test, which will save laboratories time and expense.
"We are excited to be able to contribute to the fight against H5N1 virus with our expertise and know-how. Our technology has greatly simplified and accelerated the process of detection and identification of new H5N1 variants. Such information is especially critical when the virus mutates to become more dangerous, such as in drug resistance." said Dr Inoue.
Related Links:
Agency for Science and Technology Research
Tan Tock Seng Hospital
World Health Organization
Latest Microbiology News
- Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing
- Diagnostic Stewardship Guide Targets Testing Overuse and Hospital Cost Pressures
- Infant Skin Microbiome Show Links to Later Eczema and Food Allergies
- Research Strengthens Bundibugyo Virus Outbreak Readiness with Faster Diagnostics
- Gut Microbiome Classifier Improves Colorectal Cancer Risk Stratification
- New Diagnostic Workflow Identifies Bloodstream Pathogens and Antibiotic Response in Hours
- Genetic Marker Identifies Emerging Resistance to Frontline Malaria Drugs
- Surveillance and Susceptibility Testing Track Rising Candida Auris in U.S.
- Plasma Cell-Free DNA Test Enables Earlier Diagnosis of Invasive Fungal Infections
- FDA Clears One-Hour Panel for Bloodstream Infection and AMR Detection
- Precision Screening Helps Close Hepatitis C Diagnosis and Treatment Gaps
- Proteomic Workflow Maps Microbial and Host Responses in Intestinal Inflammation
- Metagenomic Sequencing Enables Faster Diagnosis of Respiratory Infections in Cystic Fibrosis
- Portable Molecular Platform to Advance Point-of-Care Testing for Lassa Fever
- New Sensitive Blood Assay Detects Tuberculosis Antigen Directly in Blood
- Study Highlights Need for Routine Hepatitis E Testing in Cirrhosis
Channels
Clinical Chemistry
view channel
Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection
Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more
Machine Learning Supports Targeted Screening for Elevated Lipoprotein(a)
Lipoprotein(a) is an independent, genetically determined risk factor for atherosclerotic cardiovascular disease, yet routine screening remains uncommon despite guideline recommendations, leaving many high-risk... Read more
Blood Biomarker May Help Monitor Early Response to Lecanemab in Alzheimer’s Disease
Alzheimer’s disease is a progressive neurodegenerative disorder marked by amyloid-beta and tau pathology and remains a leading cause of cognitive decline in older adults. Although lecanemab, an anti-amyloid... Read moreMolecular Diagnostics
view channel
Rapid CRISPR Test Identifies Nontuberculous Mycobacteria Species from Respiratory Samples
Chronic lung infections caused by nontuberculous mycobacteria (NTM) are increasingly recognized but frequently mistaken for tuberculosis, complicating diagnosis and care. These infections may affect as... Read more
FDA Clears Compact Molecular COVID Test for Decentralized Care Settings
Decentralized healthcare settings such as urgent care clinics have historically struggled to deploy high-performance molecular testing. Barriers include high upfront costs, fixed testing capacity, large... Read moreHematology
view channel
New Automated Hemostasis Systems Become Available Across US Laboratories
Hemostasis testing supports critical decisions in surgery, anticoagulation management, and the evaluation of bleeding and thrombotic disorders, but laboratories continue to face rising volumes and complex... Read more
Variation in AML Residual Disease Testing Prompts Push for Standardization
Acute myeloid leukemia (AML) is an aggressive blood cancer in which relapse after therapy remains a persistent challenge, making measurable residual disease (MRD) detection central to risk assessment and... Read moreImmunology
view channel
Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead
Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more
New Cellular Map May Help Predict Crohn’s Disease Course in Children
Crohn’s disease in children is a common and debilitating form of inflammatory bowel disease, marked by chronic intestinal inflammation and limited pediatric-specific treatments. Clinicians must decide... Read more
Temporal Immune Profiling Reveals How Sepsis States Change Over Time
Sepsis is a life-threatening condition in which the immune response to infection becomes dysregulated, leading to rapid organ failure and death. Although antimicrobials and organ support remain standard... Read more
Study Identifies Immune Cells That Drive Harmful Autoantibody Responses in COVID-19
Autoantibodies that mistakenly attack the body’s own tissues have been linked to severe COVID-19, Long COVID, and increased risk of autoimmune disease. However, the origins of these autoantibodies during... Read morePathology
view channel
Tumor Budding Grading May Predict Chemotherapy Benefit in Resected Lung Squamous Cancer
Outcomes after resection for lung squamous cell carcinoma (SqCC) vary substantially, and the uneven benefit of adjuvant chemotherapy complicates postsurgical treatment decisions. Pathologic markers that... Read more
CAP Updates Cancer Protocols to Refine Breast Cancer Biomarker Reporting and GIST Molecular Testing
Standardized biomarker reporting and molecular profiling are central to pathology-driven cancer care, but evolving practices require laboratories to keep reporting templates current. These templates capture... Read moreTechnology
view channel
ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine
Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more
Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions
Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more
New Multipurpose Centrifuge Combines High Capacity with Sustainable Cooling
Laboratories often need centrifugation that accommodates multiple vessel formats while maintaining controlled temperatures to protect sensitive samples. Intuitive controls and repeatable operation can... Read more
Bacterial Vesicle Expression System Streamlines Production of Cancer Diagnostic Proteins
Recombinant proteins are central to many cancer diagnostics and therapies, but numerous targets remain difficult and costly to produce because they are unstable, toxic to microbial hosts, or require precise folding.... Read moreIndustry
view channel
Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities
Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Unilabs Expands Digital Pathology Across European Network with Proscia Platform
As precision medicine expands, digital pathology platforms must connect teams, sites, diagnostic data, and artificial intelligence to accelerate routine diagnosis. Sharing expertise across laboratory networks... Read more
MGI Launches Automated Multiplex Tissue Staining and Imaging System at ECP 2026
MGI Tech Co., Ltd. (Shenzhen, China) introduced VisiOmics (PMIF-20RS), a fully automated multiplex immunofluorescence staining and imaging system, at the 38th European Congress of Pathology (ECP 2026)... Read more







